Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto von Loibl, S., Weber, K.E., Timms, K.M., Elkin, E.P., Hahnen, E., Fasching, P.A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C.T., Rezai, M., Blohmer, J.U., Zahm, D.M., Jackisch, C., Gerber, B., Klare, P., Kümmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A.-R., von Minckwitz, G., Untch, M.

Volltext

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis von Emens, L.A., Adams, S., Barrios, C.H., Diéras, V., Iwata, H., Loi, S., Rugo, H.S., Schneeweiss, A., Winer, E.P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Patel, S., Chui, S.Y., Schmid, P.

Volltext

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and b... von Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

Volltext

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally adv... von Miles, D., Gligorov, J., Cameron, D., Xu, B., Semiglazov, V., Reinisch, M., Patre, M., Morales, L., Patel, S.L., Barata, T., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Sun, T., Yang, J., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Colleoni, M., Cortesi, L., Placido, S., Ferrau, F., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Tredan, O., Gligorov, J., Timar David, M., Dohollou, N., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Aleixo, S., Junior, R., Reinisch, M., Grischke, E.-M., Harbeck, N., Peters, U., Fischer, D., Forstbauer, H., Warner, E., Bouganim, N., Vandenberg, T., Pavic, M., Robinson, A., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Cubukcu, E., Wardley, A., Miles, D., Gupta, S., Mohapatra, P., Ghadyalpatil, N., Singhal, M., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Ben Baruch, N., Hamilton, E., Brufsky, A., Wright, G., Graff, S., Semiglazov, V., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Sagara, Y., Yanagita, Y., Kaen, D., Nervo, A., Melichar, B., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Papandreou, C.

Volltext

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early brea... von Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J.H., Tsai, Y.-F., Ratnayake, J., McNally, V., Ross, G., Cortés, J.

Volltext

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response von Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.-U., Furlanetto, J., Zahm, D.-M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P.A., Nekljudova, V., Denkert, C., Untch, M.

Volltext

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) von Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W.D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R.K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J.-U., Loibl, S.

Volltext

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? von Schaefgen, B., Mati, M., Sinn, H. P., Golatta, M., Stieber, A., Rauch, G., Hennigs, A., Richter, H., Domschke, C., Schuetz, F., Sohn, C., Schneeweiss, A., Heil, Joerg

Volltext

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo von Karn, T., Denkert, C., Weber, K.E., Holtrich, U., Hanusch, C., Sinn, B.V., Higgs, B.W., Jank, P., Sinn, H.P., Huober, J., Becker, C., Blohmer, J.-U., Marmé, F., Schmitt, W.D., Wu, S., van Mackelenbergh, M., Müller, V., Schem, C., Stickeler, E., Fasching, P.A., Jackisch, C., Untch, M., Schneeweiss, A., Loibl, S.

Volltext

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial von Jaeger, B A S, Neugebauer, J, Andergassen, U, Melcher, C, Schochter, F, Mouarrawy, D, Ziemendorff, G, Clemens, M, V Abel, E, Heinrich, G, Schueller, K, Schneeweiss, A, Fasching, P, Beckmann, M W, Scholz, Ch, Friedl, T W P, Friese, K, Pantel, K, Fehm, T, Janni, W, Rack, B

Volltext

MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways von Keklikoglou, I, Koerner, C, Schmidt, C, Zhang, J D, Heckmann, D, Shavinskaya, A, Allgayer, H, Gückel, B, Fehm, T, Schneeweiss, A, Sahin, Ö, Wiemann, S, Tschulena, U

Volltext

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer von Adams, S., Diéras, V., Barrios, C.H., Winer, E.P., Schneeweiss, A., Iwata, H., Loi, S., Patel, S., Henschel, V., Chui, S.Y., Rugo, H.S., Emens, L.A., Schmid, P.

Volltext

Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) von Gouda, M.A., Janku, F., Wahida, A., Buschhorn, L., Schneeweiss, A., Abdel Karim, N., De Miguel Perez, D., Del Re, M., Russo, A., Curigliano, G., Rolfo, C., Subbiah, V.

Volltext

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized c... von Llop-Guevara, A., Loibl, S., Villacampa, G., Vladimirova, V., Schneeweiss, A., Karn, T., Zahm, D.-M., Herencia-Ropero, A., Jank, P., van Mackelenbergh, M., Fasching, P.A., Marmé, F., Stickeler, E., Schem, C., Dienstmann, R., Florian, S., Nekljudova, V., Balmaña, J., Hahnen, E., Denkert, C., Serra, V.

Volltext

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from t... von Yardley, D.A., Coleman, R., Conte, P., Cortes, J., Brufsky, A., Shtivelband, M., Young, R., Bengala, C., Ali, H., Eakel, J., Schneeweiss, A., de la Cruz-Merino, L., Wilks, S., O’Shaughnessy, J., Glück, S., Li, H., Miller, J., Barton, D., Harbeck, N.

Volltext

Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade von Hennigs, A., Riedel, F., Marmé, F., Sinn, P., Lindel, K., Gondos, A., Smetanay, K., Golatta, M., Sohn, C., Schuetz, F., Heil, J., Schneeweiss, A.

Volltext

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 von Kaufmann, M., von Minckwitz, G., Bear, H.D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., Makris, A., Miller, W., Pierga, J.-Y., Semiglazov, V., Schneeweiss, A., Souchon, R., Stearns, V., Untch, M., Loibl, S.

Volltext

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial von Loibl, S., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Wiebringhaus, H., Kümmel, S., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Clemens, M., Dan Costa, S., Gerber, B., Engels, K., Nekljudova, V., von Minckwitz, G., Untch, M.

Volltext

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer von Bell, R., Brown, J., Parmar, M., Toi, M., Suter, T., Steger, G.G., Pivot, X., Mackey, J., Jackisch, C., Dent, R., Hall, P., Xu, N., Morales, L., Provencher, L., Hegg, R., Vanlemmens, L., Kirsch, A., Schneeweiss, A., Masuda, N., Overkamp, F., Cameron, D.

Volltext

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change... von Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., Blohmer, J.

Volltext